Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals

Among Four Key Aspects That Will Underpin US Generics Business In 2021

 
• By Dave Wallace
  
Four Cogs Hands Sunset
Four key “moving pieces” will influence the success of Hikma’s US generics business in 2021 • Source: Shutterstock

More from Strategy

More from Business